Loading...
XSHG600161
Market cap5.69bUSD
Dec 24, Last price  
20.98CNY
1D
2.24%
1Q
-2.69%
Jan 2017
-10.00%
Name

Beijing Tiantan Biological Products Corp Ltd

Chart & Performance

D1W1MN
XSHG:600161 chart
P/E
37.38
P/S
8.01
EPS
0.56
Div Yield, %
0.20%
Shrs. gr., 5y
5.72%
Rev. gr., 5y
12.06%
Revenues
5.18b
+21.57%
290,049,411343,358,631413,781,166530,504,687682,700,4311,100,252,9751,202,261,4091,394,395,3411,502,351,1601,836,504,0831,826,551,1271,617,985,9812,095,734,3011,765,169,6792,931,058,7283,281,859,5603,445,594,8654,112,155,6214,261,304,6225,180,441,799
Net income
1.11b
-7.88%
47,531,74768,999,532101,045,654104,702,668133,381,727211,659,754174,924,348233,349,955304,911,661372,028,783128,391,6739,977,207261,777,4411,179,942,696509,479,066894,253,782943,076,5911,068,813,8181,204,834,6911,109,888,597
CFO
2.39b
+112.57%
110,105,781131,685,718154,361,978153,548,280276,390,256448,226,847184,854,393353,150,675432,004,890566,433,984477,952,523473,258,905428,374,721218,389,433677,916,885642,468,858702,109,603980,350,1951,126,002,1902,393,576,031
Dividend
Jun 20, 20240.15 CNY/sh
Earnings
Apr 24, 2025

Profile

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.
URL
https://www.tiantanbio.com/
IPO date
Jun 16, 1998
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,180,442
21.57%
4,261,305
3.63%
4,112,156
19.35%
Cost of revenue
3,159,525
2,643,916
2,639,144
Unusual Expense (Income)
NOPBT
2,020,916
1,617,389
1,473,012
NOPBT Margin
39.01%
37.96%
35.82%
Operating Taxes
289,140
221,438
172,204
Tax Rate
14.31%
13.69%
11.69%
NOPAT
1,731,777
1,395,951
1,300,808
Net income
1,109,889
-7.88%
1,204,835
12.73%
1,068,814
13.33%
Dividends
(82,390)
(137,317)
(137,317)
Dividend yield
0.13%
0.35%
0.30%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
123,806
124,659
Long-term debt
48,830
304,983
402,279
Deferred revenue
101,904
92,686
Other long-term liabilities
100,801
4,105
4,105
Net debt
(4,652,184)
(3,501,984)
(4,057,301)
Cash flow
Cash from operating activities
2,393,576
1,126,002
980,350
CAPEX
(1,077,540)
Cash from investing activities
(1,280,657)
Cash from financing activities
(508,084)
2,774,371
FCF
1,509,879
(21,254)
433,883
Balance
Cash
4,554,949
3,712,890
4,329,748
Long term investments
146,065
217,883
254,492
Excess cash
4,441,992
3,717,707
4,378,632
Stockholders' equity
9,700,077
8,660,560
7,296,449
Invested Capital
8,437,594
8,010,385
6,385,587
ROIC
21.06%
19.39%
22.79%
ROCE
15.66%
13.74%
13.66%
EV
Common stock shares outstanding
1,977,372
1,647,810
1,600,316
Price
30.94
30.38%
23.73
-18.06%
28.96
-30.55%
Market cap
61,179,875
56.46%
39,102,520
-15.63%
46,345,140
-26.17%
EV
59,459,482
38,161,135
44,502,674
EBITDA
2,288,941
1,797,136
1,630,166
EV/EBITDA
25.98
21.23
27.30
Interest
6,001
2,411
3,089
Interest/NOPBT
0.30%
0.15%
0.21%